Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of venetoclax when given
together with azacitidine in treating patients with high-risk myelodysplastic syndrome that
has come back (recurrent) or does not respond to treatment (refractory). Drugs used in
chemotherapy, such as venetoclax and azacitidine, work in different ways to stop the growth
of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading.